Supreme Court Keeps Mifepristone Mail Access Alive — For Now — as Louisiana’s Anti-Abortion Lawsuit Threatens National Drug Regulation
The US Supreme Court issued a temporary order Monday preserving nationwide access to mail-order mifepristone, blocking a lower court’s attempt to ban the abortion medication’s distribution by mail and telehealth. The stay, extended by Justice Samuel Alito through at least May 14, buys time as the court weighs its next steps in a case with sweeping implications — not just for abortion access, but for the entire US pharmaceutical regulatory system.
How We Got Here
Louisiana sued the Food and Drug Administration last fall, challenging the agency’s 2023 rule allowing mifepristone to be prescribed remotely and shipped by mail. The state argues the practice circumvents its own abortion ban — and that the FDA’s rule was not grounded in science, potentially violating the Administrative Procedure Act.
On May 1, the US Court of Appeals for the Fifth Circuit sided with Louisiana and ordered a ban on mailing the drug. Two mifepristone manufacturers immediately filed an emergency appeal to the Supreme Court. Alito, who handles emergency requests from the Fifth Circuit, issued a temporary stay on May 4 and extended it Monday.
A Shadow-Docket Decision With Major Stakes
The ruling came through the Supreme Court’s so-called shadow docket — a procedural mechanism for emergency orders that bypasses full briefing and oral argument. Critics have long warned the shadow docket is being used to make consequential policy decisions with minimal transparency or accountability.
Notably absent from the case is the US government itself. Despite the lawsuit directly targeting FDA authority, the Trump administration has not intervened to defend the agency’s rules. Former FDA leaders, researchers, and lobbyists filed amicus briefs — but the government’s silence speaks volumes about where the administration’s priorities lie.
The Comstock Gambit
Louisiana’s legal strategy includes invoking the Comstock Act, an 1873 anti-obscenity law that anti-abortion advocates have sought to weaponize against reproductive healthcare. The argument that a 150-year-old law prohibiting “obscene” materials in the mail can be used to ban FDA-approved medication represents one of the more radical legal theories in contemporary reproductive rights litigation.
The same law firm representing Louisiana — Alliance Defending Freedom — brought the 2024 case FDA v. Alliance for Hippocratic Medicine, in which the Supreme Court unanimously ruled that the anti-abortion coalition lacked standing because it could not demonstrate concrete harm. ADF is now trying a different legal avenue through state government.
What’s Actually at Stake
The consequences of Louisiana prevailing would extend far beyond abortion. If a single state can effectively override FDA drug approvals and distribution rules, it would shatter the federal government’s authority to regulate medications uniformly across the country.
Legal and medical experts warn this would open the door to states banning or restricting any FDA-approved drug they find politically objectionable — a precedent with profound implications for the entire pharmaceutical industry.
The FDA had requested additional time to complete a safety review of mifepristone, and a judge ruled in April that proceedings would pause until that review concluded. Louisiana appealed that pause, forcing the issue back into the courts before the review was finished.
Providers Prepare Contingency Plans
Abortion providers are not waiting for the courts to act. If mifepristone access is ultimately restricted, clinics and telehealth services have protocols in place to offer misoprostol-only regimens, which can also end pregnancies — though the process takes longer and may cause greater discomfort for patients.
The next deadline is May 14, when the Supreme Court’s current stay expires. The court has not yet indicated whether it will take up the case on the merits or allow the Fifth Circuit’s ruling to take effect.